These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6348681)

  • 21. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of platelet alloimmunization.
    Slichter SJ
    Prog Clin Biol Res; 1986; 211():83-116. PubMed ID: 3515365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of blood components in hemotherapy on the factors of anti-infectious protection in patients with acute leukemias].
    Martynova VA; Abakumov EM; Ermakova GL; Pobedinskaia IN
    Gematol Transfuziol; 1988 Aug; 33(8):16-9. PubMed ID: 3192049
    [No Abstract]   [Full Text] [Related]  

  • 24. Platelet and granulocyte transfusions in cancer patients.
    Dutcher JP
    Adv Immun Cancer Ther; 1986; 2():211-49. PubMed ID: 3321947
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
    Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
    Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components.
    Saarinen UM; Kekomäki R; Siimes MA; Myllylä G
    Blood; 1990 Jan; 75(2):512-7. PubMed ID: 2295005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Transfusion of platelet concentrates].
    Rieux C; Lee K; Lavaud A; Bierling P
    Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical aspects of platelet transfusion.
    Williamson LM
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):643-6. PubMed ID: 1333290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow transplantation in patients with leukaemia previously transfused with blood products from family members.
    Ho WG; Champlin RE; Winston DJ; Feig SA; Gale RP
    Br J Haematol; 1987 Sep; 67(1):67-70. PubMed ID: 3311126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors.
    Benson K; Marks AR; Marshall MJ; Goldstein JD
    Transfusion; 1994 May; 34(5):432-7. PubMed ID: 8191569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet transfusion from donors mismatched for crossreactive HLA antigens.
    Dahlke MB; Weiss KL
    Transfusion; 1984; 24(4):299-302. PubMed ID: 6464151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
    Eernisse JG; Brand A
    Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfusion therapy in critically ill children.
    Chang TT
    Pediatr Neonatol; 2008 Apr; 49(2):5-12. PubMed ID: 18947009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. The use of platelet transfusions.
    Feusner J
    Am J Pediatr Hematol Oncol; 1984; 6(3):255-60. PubMed ID: 6393789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization.
    Murphy MF; Metcalfe P; Thomas H; Eve J; Ord J; Lister TA; Waters AH
    Br J Haematol; 1986 Mar; 62(3):529-34. PubMed ID: 3954967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of HLA-alloimmunization of recipients of platelet concentrates].
    Kuntz BM; Wollenhaupt HJ; Brüster HT
    Beitr Infusionsther; 1991; 28():209-12. PubMed ID: 1725621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.
    Petz LD; Garratty G; Calhoun L; Clark BD; Terasaki PI; Gresens C; Gornbein JA; Landaw EM; Smith R; Cecka JM
    Transfusion; 2000 Dec; 40(12):1446-56. PubMed ID: 11134563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.